Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of clazosentan for prevention of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
MOH_2018-11-18_004785Phase 3Recruiting
- Sponsor
- Idorsia
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Clazosentan continuous infusion with Placebo continuous infusion (2 arms). Primary endpoint: Clinical deterioration due to delayed cerebral ischemia. Started Oct 2018; status: recruiting.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on MOH_2018-11-18_004785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-18_004785.